Vera Therapeutics (VERA), a late clinical-stage biotechnology company, announced on Wednesday that it has granted inducement awards to six new employees.
The awards consist of non-qualified stock options to purchase 35,250 shares of Class A common stock and restricted stock units (RSUs) for 17,625 shares of Class A common stock.
The stock options have an exercise price of $42.19 per share, which was the closing price on January 8, 2025.
The options will vest over four years, with 25% of the shares vesting on the first anniversary of the vesting commencement date and the remaining balance vesting monthly over the next 36 months.
The RSUs will vest over four years, with 25% vesting each year on February 20th, starting in 2025.
The inducement grants were approved by Vera's Compensation Committee as part of the company's effort to attract new talent, in accordance with Nasdaq Listing Rule 5635(c)(4).
The grants are designed to incentivize continued service with the company as it advances its treatments for serious immunological diseases.
Vera's lead product candidates include atacicept, a treatment for autoimmune diseases like IgA nephropathy (IgAN) and lupus nephritis, and MAU868, a monoclonal antibody targeting BK virus.
Currently, VERA is trading at $34.68 up by 0.26%.
For comments and feedback: editorial@rttnews.com